Shiffrin says in essay she feels 'like myself again' after recovering from ski racing crash, PTSD
Shiffrin described in an essay for The Players' Tribune released Friday the physical and mental hurdles she needed to clear after her serious spill during a giant slalom race in Killington, Vermont, on Nov. 30. In the crash, something punctured Shiffrin's side and caused severe damage to her oblique muscles.
'Everyone knows what it feels like to have a bad cough. But PTSD … it's not like that,' the 30-year-old from Edwards, Colorado, wrote. 'It comes in all shapes and sizes. Everyone experiences it in their own way, and no two cases are exactly alike.'
Shiffrin was leading after the first run of the GS that day in Killington. With the finish line in sight on her final run, she lost an edge and slid into a gate, flipping over her skis. The all-time winningest Alpine World Cup ski racer then slammed into another gate before coming to a stop in the protective fencing. To this day, she doesn't know what led to the puncture wound, only that it was 'a millimeter from pretty catastrophic,' she told The Associated Press.
Shiffrin wrote in The Players' Tribune it was 'difficult to explain what the pain felt like. But the closest I can get would probably be, it was like … not only was there a knife stabbing me, but the knife was actually still inside of me.'
In late January, Shiffrin returned to the World Cup circuit. The giant slalom, though, remained a cause of anxiety and she skipped the event at world championships.
Ever so steadily, she's working on overcoming the mental trauma surrounding the GS as she gears up for the 2026 Milan-Cortina Winter Games. She won an Olympic gold medal in the discipline at the 2018 Pyeongchang Games.
She's been working with a psychologist to conquer her mental obstacles.
'I can admit that there were some extremely low moments,' recounted Shiffrin, who won her 100th career World Cup ski race in February. 'Times when I started second-guessing myself, or was critical of myself because I felt like I was letting what happened mess with me so much. It was like: Come on, Mikaela, people have had way worse crashes than that, way worse injuries. Those people got through it. What is wrong with you?
'On particularly bad days, I'd question my motivation, or whether I still wanted to do this anymore. In my head, I'd be saying to myself: You know what, I kind of couldn't care less if I ever race again.'
She and the therapist began looking at her recovery through the prism of PTSD.
'With me, I also think it's possible that the crash I had at the beginning of 2024 in Cortina, and then Killington happening. … that those two crashes maybe built on one another,' Shiffrin said. 'I talked with my therapist about that, and she let me know that past trauma, or a history of traumatic events, can sometimes affect your reaction to new traumatic events.'
She lost her dad, Jeff, five years ago in a home accident. Her fiancé and fellow ski racer Aleksander Aamodt Kilde of Norway is still recovering from a serious ski crash on Jan. 13, 2024.
'Maybe when I crashed and got that puncture wound, maybe that was kind of a perfect-storm situation for PTSD to take hold,' Shiffrin wrote.
Shiffrin said one thing that's helped is 'getting back to a place of joy.' She closed her essay with: 'All I can do is smile with appreciation. Because, finally .... I feel like myself again.'
___
AP skiing: https://apnews.com/hub/alpine-skiing
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Travis Hunter to play both ways during Jaguars' preseason opener against Steelers
Jacksonville Jaguars head coach Liam Coen told reporters Thursday that his starters will see the field Saturday in the team's preseason opener against the Pittsburgh Steelers. That, of course, includes No. 2 overall pick and two-way star Travis Hunter, who Coen said will in fact play both ways versus the Steelers. Meanwhile, Pittsburgh is taking a different approach. Longtime Steelers head coach Mike Tomlin announced an extensive list of starters who will be healthy scratches for the exhibition. That group includes quarterback Aaron Rodgers; wide receiver DK Metcalf; tight ends Jonnu Smith and Pat Freiermuth; running back Jaylen Warren; cornerbacks Jalen Ramsey, Joey Porter Jr. and Darius Slay; defensive end Cameron Heyward and linebacker T.J. Watt, among others. "It has nothing to do with injury," Tomlin said. "They need less runway to take off, to be quite honest with you. Because of their experience and where they are in their careers, oftentimes I preserve them through this process while providing more opportunity for those that need more preparation or more opportunity to display their talents and so forth." While fans will have to wait to see what Rodgers looks like in the Pittsburgh offense, it looks like they'll get a glimpse of Hunter on both sides of the ball in Jacksonsville. Hunter, last year's Heisman Trophy winner, is listed as a starting wideout and backup cornerback on the Jaguars' first first unofficial depth chart, which the team released Monday. The 6-foot-1, 185-pound phenom is coming off a prolific final season at Colorado, where he played 753 snaps on offense, 776 on defense and 23 more on special teams in 2024, according to Pro Football Focus. In the process, he caught 96 passes for 1,258 yards and 15 touchdowns, plus he ran for one additional score. At cornerback, he picked off four passes and notably forced a fumble that clinched an overtime victory against Baylor. During training camp, Jacksonville eased Hunter into practicing both positions, allowing him time to fully focus on each playbook before playing two ways in the same day. Coen went on the "The Rich Eisen Show" on Monday and suggested 80% of the Jags' offensive snaps as a potential game-by-game target for Hunter this season, with the hope of him trying to match that snap count percentage on defense as well. "We've done more offense because that was where more of the development was necessary," Coen said Monday of Hunter's work in camp, via "The Rich Eisen Show." "It's so much more natural [for him] to just go walk out on the field and play corner. That's what he's done. He can go do that. Now, there's a lot of checks, there's a lot of calls, there's a lot of different things that go to that. But offensively, we felt like there was a little bit more development that was necessary, and it's a lot more ball — just a lot more scheme and words and calls. "Every single day is completely packed, from the moment that he arrives to the moment he leaves, with making sure that he is meeting with somebody at all times." Eisen proposed that Hunter could even win both NFL Offensive and Defensive Rookie of the Year awards this season, and Coen agreed that "it's possible." That journey officially begins in Week 1 against the Carolina Panthers. But Saturday's preseason game against the Steelers will provide a sneak peek at how Hunter's two-way skill set translates to the NFL.
Yahoo
18 minutes ago
- Yahoo
Caitlin Clark's next game: How to watch the 2025 WNBA season, full schedule, TV channels and more
Caitlin Clark is in her sophomore season with the Indiana Fever this year. With the WNBA growing from 12 to 13 teams this season and former UConn superstar and current-rookie Paige Bueckers joining the mix that already includes Angel Reese, A'ja Wilson and Breanna Stewart, Clark isn't the only big name about to hit the court. But, she remains a fan-favorite. If you're trying to keep up with Caitlin Clark's WNBA season, we've got you covered. Here are the best ways to watch every one of the Indiana Fever's games in 2025. How to watch Caitlin Clark's next game: Date: Thursday, August 7 Time: 10 p.m. ET TV channel: Prime Video Streaming: Fubo and more When is Caitlin Clark's next game? The Indiana Fever will face the Phoenix Mercury tonight, August 7. But Clark won't play tonight due to injury. 2025 WNBA season schedule: You can check out Caitlin Clark's full WNBA season schedule (including which channel every game is airing on) here. Indiana Fever WNBA schedule for August: All times Eastern Thursday, Aug 7, 2025 Indiana Fever vs. Phoenix Mercury: 10:00 p.m. ET (Prime Video, Local) Saturday, Aug 9, 2025 Chicago Sky vs. Indiana Fever: 8:00 p.m. ET (CBS) Tuesday, Aug 12, 2025 Dallas Wings vs. Indiana Fever: 7:30 p.m. ET (ESPN) Friday, Aug 15, 2025 Washington Mystics vs. Indiana Fever: 7:30 p.m. ET (ION, League Pass) Sunday, Aug 17, 2025 Indiana Fever vs. Connecticut Sun: 1:00 p.m. ET (NBA TV, Local, League Pass) Friday, Aug 22, 2025 Minnesota Lynx vs. Indiana Fever: 7:30 p.m. ET (ION, League Pass) Sunday, Aug 24, 2025 Indiana Fever vs. Minnesota Lynx: 7:00 p.m. ET (CBS Sports Network, Local) Tuesday, Aug 26, 2025 Seattle Storm vs. Indiana Fever: 7:00 p.m. ET (CBS Sports Network, Local) Friday, Aug 29, 2025 Indiana Fever vs. Los Angeles Sparks: 10:00 p.m. ET (ION, League Pass) Sunday, Aug 31, 2025 Indiana Fever vs. Golden State Valkyries: 8:30 p.m. ET (NBA TV, Local, League Pass) What channels do I need to watch WNBA games live this season? This season, you can catch a record number of WNBA games airing across the Disney Networks: 13 games on ESPN, 2 on ESPN3, and 13 games on ABC/ESPN+, including an opening weekend doubleheader on May 17 between the Las Vegas Aces and the New York Liberty at 1 p.m. ET and the Chicago Sky vs. Indiana Fever at 3 p.m. ET. Come September, Disney Networks will also exclusively air the WNBA Playoffs – up to 29 games – including the WBNA Finals. Select games streaming on ESPN+ will also be available on Disney+ if you have a Disney+/ESPN+ streaming bundle. While it can be hard to keep track of every way to watch the WNBA, one good rule of thumb to remember is that Prime Video owns Thursday nights and ION is home to most Friday games. You can catch 20 matchups throughout the season on WNBA on Prime Video, and stream the Championship Game of the WNBA Commissioner's Cup mid-season tournament. For Friday games, ION will broadcast 50 games over the regular season as part of its 'State Farm WNBA Friday Night Spotlight,' which features a weekly doubleheader In addition, 40 games will air on NBA TV, 20 games will air on CBS Sports, and in a first, CBS will air the first-ever network broadcast of the WNBA in primetime; on June 7 and August 9, the Chicago Sky will face off against the Indiana Fever for nationally broadcast evening games on the channel. And for even more coverage, don't forget that WNBA League Pass will also be streaming over 200 games this season (blackouts apply), and many games will be airing in local markets. You can find out which local channels will broadcast which games on the WNBA schedule. With so many channels and streaming platforms, here's a breakdown of the best ways to watch the WNBA this season without subscribing to all the things and paying all the money. How to watch WNBA live or stream WNBA games in 2025: How to watch the WNBA season with WNBA League Pass: More ways to watch the 2025 WNBA season:
Yahoo
18 minutes ago
- Yahoo
Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
